Partnership in the picture: providing comprehensive support with InfarAMA
At e&a consultants, we want to support our clients fully. Bringing medicine to market, however, involves more than market access. To help you cover all facets of your product journey, we partner with strong experts in the field. One such partner is InfarAMA, which specialises in regulatory affairs, product vigilance, and quality assurance. Johan Eykens sat down with InfarAMA’s managing directors, Marian Coquel and Kristl Vandenbussche, to discuss the partnership’s strengths.
Marian and Kristl, why did you decide to partner with e&a consultants?
Kristl: There’s a close synergy between registration and medicine pricing. The medical info that comes to surface during the registration process can be important to the pricing and market positioning of medicine. Therefore, it is in the client's interest to involve a market access department or partner in that process. To completely service our clients, it was important to us to find a market access partner we could trust.
Marian: I’ve known Johan for over twenty years. We have always worked well together as colleagues and consultants. Our companies share the same philosophy. We both have a pragmatic, no-nonsense approach and prioritise customised service. That match made it easy to form a partnership.
What does the partnership look like?
Kristl: If a new client wants to launch a product, we can handle regulatory affairs and help them contact e&a consultants, our preferred partner for market access. If the client agrees, we can collaborate closely on their project, which can speed up the process.
Marian: It also happens that one of our existing clients wants to change the packaging or dosage strength of a product, which can influence the pricing. In that case, we refer them to e&a consultants, which can offer support in that area.
Johan: Likewise, when clients come to us with questions about obtaining permits or other legal requirements, we bring them in touch with InfarAMA. By referring to each other in this way, we want to provide clients with total service for their short—and long-term projects.
How do you ensure smooth and strong collaboration?
Johan: Our collaboration is not just project-based; we also actively exchange knowledge. Our consultants have previously given market access training to InfarAMA’s employees as part of their onboarding.
Kristl: Knowledge exchange is crucial to our partnership. If I have any pricing-related questions, all I have to do is send Johan an email. By better understanding what e&a consultants does, we know when to refer clients to them and what information to share when collaborating on a project.
Marian: Knowing what quality the other offers allows you to fully trust each other and refer to them confidently. The client notices that trust.
Finally, what benefits does this partnership offer clients?
Johan: In short, clients needing support in market access and regulatory affairs can count on a very efficient partnership to manage their case. Because we understand each other’s expertise so well, we can easily exchange information or consult one another in case of questions, if the client agrees to that. This makes handling a case so much easier.
Kristl: Most importantly, unlike large international consultants, our partnership bundles focus and knowledge of procedures in the Benelux, allowing us to offer more customised service. That is our biggest asset.
Do you need support in bringing your medicine to market? Schedule a strategic meeting with e&a consultants and InfarAMA around the table for a fully covered plan of approach.
Introducing our new colleague, Lena!
We’re excited to welcome Lena Dumortier as the latest addition to the e&a consultants team! Joining us as a Market Access Associate Consultant, Lena brings her passion for helping patients and her background in pharmacy.
Explaining the reformed reimbursement procedure in Belgium
In May 2024, a major reform of medicine reimbursement in Belgium was approved by the Parliament. This reform is now also published into the Belgian Official Gazette. But how will these changes impact pharma companies and patients?
Market access intern Chloé on her internship at e&a consultants
After nine months, Chloé’s internship at e&a consultants has come to an end, the perfect opportunity for her to look back on the highlights and learnings of this period with her supervisor, Arne.
It’s official: the reimbursement procedure for medicine will be reformed!
Last week a major reform of the reimbursement procedure for medicine was approved. But what does that mean for you as a patient or for your pharma company? e&a consultants summarises the key points for you.
Collect your real-world data with Carebytes
In partnership with healthcare software developer Carebytes, e&a consultants has designed a real-world data platform, customisable to your needs and with GDPR compliance.
e&a consultants introduces pharma students to market access
e&a consultants co-organises an Orientation Day to introduce master pharma students at the KU Leuven to consultancy and other career paths. Why the need for this event? Managing director Johan Eykens and senior associate consultant Lotte Herbots are happy to tell you.
New colleague in the picture: meet office assistant Elodie
We could never support our clients as well as we do without our top-notch team. Meet our newest colleague, office assistant Elodie Recio Martinez.
e&a consultants looks back at 2023: new team, new platform, new laws
Managing Director Johan Eykens looks back on 2023, a year full of changes for e&a consultants. What was their greatest milestone in 2023? What are the challenges to come? Find out in this interview.
We wish you a sparkling 2024
As 2024 approaches, we are filled with excitement. Because along with the new year, a thrilling new chapter for e&a consultants begins.